Sanofi-Aventis, Bristol Myers Squibb file motion to stop sales of Apotex' generic Plavix

By Lisa Kerner

Charlotte, N.C., Aug. 14 - Sanofi-Aventis and Bristol-Myers Squibb filed a motion in the U.S. District Court for the Southern District of New York for a preliminary injunction ordering Apotex Inc. and Apotex Corp. to stop selling a generic version of clopidogrel bisulfate product that competes with Plavix.

The filing follows Apotex's launch of a generic version of clopidogrel bisulfate 75 mg tablets.

A hearing for the motion is scheduled for Friday, according to a news release.

Apotex is a Weston, Ont., generic medicine provider.

Bristol-Myers Squibb is a pharmaceutical company located in New York.

Sanofi-Aventis is a Paris-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.